SWM
LGND icon

Spire Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Spire Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$7.31K – 2316
2024
Q1 		$7.31K Hold
100
– – ﹤0.01% 1813
2023
Q4 		$7.25K Hold
100
– – ﹤0.01% 1842
2023
Q3 		$5.99K Hold
100
– – ﹤0.01% 1892
2023
Q2 		$7.21K Hold
100
– – ﹤0.01% 1904
2023
Q1 		$7.36K Buy
+100
New +$7.11K ﹤0.01% 1946
2022
Q3 		– Sell
-16
Closed -$1K – 2424
2022
Q2 		$1K Sell
16
-144
-90% -$8.17K ﹤0.01% 2534
2022
Q1 		$11K Hold
160
– – ﹤0.01% 2000
2021
Q4 		$15K Hold
160
– – ﹤0.01% 2224
2021
Q3 		$14K Hold
160
– – ﹤0.01% 1989
2021
Q2 		$13K Hold
160
– – ﹤0.01% 2029
2021
Q1 		$15K Buy
+160
New +$15.1K ﹤0.01% 2266

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Spire Wealth Management's LGND Position: Q2 2024 in Review

Spire Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 100 shares — an estimated $7.31K sold.

Spire Wealth Management first reported a position in LGND in Q1 2021 and held it in 11 quarters. The position peaked at $15K in Q4 2021. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Spire Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Spire Wealth Management sold 100 Ligand Pharmaceuticals shares in Q2 2024, an estimated $7.31K.
  • Spire Wealth Management first reported a position in Ligand Pharmaceuticals in Q1 2021 and held it in 11 quarters.
  • Spire Wealth Management's Ligand Pharmaceuticals position peaked at $15K in Q4 2021.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Spire Wealth Management's 13F filing for Q2 2024, filed 31 Jul 2024.